Cargando…
From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
Chronic kidney disease (CKD) is an independent risk factor for stroke and covert cerebrovascular disease, and up to 40% of stroke patients have concomitant CKD. However, the so-called “cerebrorenal interaction” attracted less attention compared to its cardiorenal counterpart. Diabetes is the leading...
Autores principales: | Hsieh, Cheng-Yang, Sung, Sheng-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820650/ https://www.ncbi.nlm.nih.gov/pubmed/36613795 http://dx.doi.org/10.3390/ijms24010351 |
Ejemplares similares
-
Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
por: Post, Adrian, et al.
Publicado: (2020) -
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
por: Beitelshees, Amber L., et al.
Publicado: (2019) -
Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
por: Chang, Sheng‐Nan, et al.
Publicado: (2023) -
Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?
por: Snaith, Jennifer R, et al.
Publicado: (2022) -
Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)